Pfizer lays out MRSA vaccine battle plan


Reuters has looked inside the Pfizer ($PFE) lab tasked with developing a vaccine for the drug-resistant superbug MRSA. Merck ($MRK) flunked late phase trials in 2011, but a host of drugmakers are still in the race. Pfizer thinks its multipronged approach can stop the bacterium. Feature

Filed Under
, , superbugs